IPP-201101

DRUG2 trials

Sponsors

ImmuPharma

Conditions

Lupus Erythematosus, Systemic

Phase 3

A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

CompletedNCT02504645

ImmuPharmaLupus Erythematosus, Systemic

Start: 2015-03-31End: 2018-01-31Updated: 2019-04-11

Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

CompletedNCT03427151

ImmuPharmaLupus Erythematosus, Systemic

Start: 2018-02-27End: 2019-02-05Updated: 2019-04-11

Related Papers

Phosphopeptides P140 cause oxidative burst responses of pulmonary macrophages in an imiquimod-induced lupus model.

2023-11-034 citations